Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136905 | 0.90 | HTR7 (0.44) | HTR1AHTR7CD274PDCD1SIGMAR1 | |
| SCHEMBL4141684 | 0.85 | BACE1 (0.37) | HTR7DYRK1ACD274SIGMAR1APP | |
| SCHEMBL4136479 | 0.82 | NAAA (0.51) | HTR1AHTR7 | |
| SCHEMBL4136395 | 0.80 | HTR2C (0.54) | HTR1AHTR7HTR2CHTR2A | |
| SCHEMBL4144409 | 0.80 | TSHR (0.38) | BACE1CCNT1CDK9DRD2 | |
| SCHEMBL4145213 | 0.80 | ADORA1 (0.42) | SIGMAR1DRD2 | |
| SCHEMBL4145755 | 0.79 | HRH3 (0.47) | HTR1AHTR7CD274PDCD1BACE1 | |
| SCHEMBL4128005 | 0.78 | CD274 (0.50) | HTR1ACD274PDCD1SIGMAR1HTR2C | |
| SCHEMBL4147542 | 0.78 | SIGMAR1 (0.38) | SIGMAR1DRD2 | |
| SCHEMBL4142775 | 0.78 | PDE7A (0.42) | SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HTR1A 19/4885HTR7 7/4885DYRK1A 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.